Form 4: Dianthus Therapeutics, Inc. /DE/ Executive Sells Shares
Insider Transaction (Form 4)
Edward Carr, CHIEF ACCOUNTING OFFICER of Dianthus Therapeutics, Inc. /DE/, sold 20,000 shares of common stock on September 17, 2026.
Summary
- Option exercise/conversion: acquired 20,000 Common Stock at $17.88 ($357,600) on September 17, 2026; holds 20,000 after (Direct).
- Open-market sale: disposed of 7,928 Common Stock at $100.43 ($796,209) on September 17, 2026; holds 12,072 after (Direct).
- Open-market sale: disposed of 6,771 Common Stock at $101.37 ($686,376) on September 17, 2026; holds 5,301 after (Direct).
- Open-market sale: disposed of 3,501 Common Stock at $102.39 ($358,467) on September 17, 2026; holds 1,800 after (Direct).
- Open-market sale: disposed of 1,100 Common Stock at $103.20 ($113,520) on September 17, 2026; holds 700 after (Direct).
- Open-market sale: disposed of 700 Common Stock at $104.39 ($73,073) on September 17, 2026 (Direct).
- Option exercise/conversion: disposed of 20,000 Stock Option (Right to Buy) on September 17, 2026; holds 43,818 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $2,027,646 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Edward Carr — Officer (CHIEF ACCOUNTING OFFICER)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-17 | Option exercise/conversion | Common Stock | 20,000 | $18 | $357.6K | 20,000 |
| 2026-09-17 | Open-market sale | Common Stock | 7,928 | $100 | $796.2K | 12,072 |
| 2026-09-17 | Open-market sale | Common Stock | 6,771 | $101 | $686.4K | 5,301 |
| 2026-09-17 | Open-market sale | Common Stock | 3,501 | $102 | $358.5K | 1,800 |
| 2026-09-17 | Open-market sale | Common Stock | 1,100 | $103 | $113.5K | 700 |
| 2026-09-17 | Open-market sale | Common Stock | 700 | $104 | $73.1K | 0 |
| 2026-09-17 | Option exercise/conversion | Stock Option (Right to Buy) | 20,000 | — | — | 43,818 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-17 | Option exercise/conversion (20,000 shares) |
| 2026-09-17 | Open-market sale (7,928 shares) |
| 2026-09-17 | Open-market sale (6,771 shares) |
| 2026-09-17 | Open-market sale (3,501 shares) |
| 2026-09-17 | Open-market sale (1,100 shares) |
| 2026-09-17 | Open-market sale (700 shares) |
| 2026-09-17 | Option exercise/conversion (20,000 shares) |
Keywords
insider transaction, Form 4, DNTH, Dianthus Therapeutics, Inc. /DE/, bearish, Edward Carr
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.